Rapidly dispersible dosage form of topiramate
View Patent ↗A taste-masked rapidly dispersible dosage form of topiramate is provided. Wax coated particles of topiramate are included within a porous bound matrix. The topiramate retains its taste-masked form after dispersion in the mouth of a subject even though the particles are not coated with a polymeric material. The dosage form disperses in saliva or water in less than 2 min even though it has a high content of wax. It can be used to treat diseases or disorders that are therapeutically responsive to topiramate or a derivative thereof.
1. A taste-masked rapidly dispersible dosage form comprising a three-dimensionally printed solid porous non-compressed bound matrix comprising:
taste-masked wax-coated particles of topiramate comprising at least one waxy material and having topiramate-to-waxy material weight ratio ranging from 20:80 to 50:50, and wherein the waxy material is not an ionic polymer or copolymer, an acrylate polymer or copolymer, a methacrylate polymer or copolymer, or an enteric polymer or copolymer;
at least one water soluble, aqueous fluid soluble, partially water soluble or partially aqueous fluid soluble binder selected from the group consisting of water-soluble synthetic polymer, polyvinlypyrrolidone, hydropropylmethylcellulose, copovidone, pre-gelatinized cornstarch, hydroxypropylcellulose, lactose, fructose, sucrose, dextrose, sorbitol, mannitol, xylitol, and a combination thereof; and
at least one surfactant selected from the group consisting of polysorbate, poloxamer, sodium lauryl sulfate, and a combination thereof; and
wherein said dosage form disperses in less than 90 sec when placed in aqueous fluid and topiramate remains taste-masked.
2. The dosage form of claim 1 , further comprising one or more components selected from the group consisting of at least one disintegrant, at least one sweetener, glycerin and at least one glidant.
3. The dosage form of claim 1 , wherein:
(a) the wax-coated particles of topiramate are prepared by spray congealing a mixture comprising molten wax and particles of topiramate;
(b) the at least one surfactant is present in an amount of up to 2 wt %, based on the total weight of the dosage form;
(c) the total amount of wax-coated particles of topiramate ranges from 20 to 50 wt %, based on the total weight of the dosage form;
(d) the hardness of the matrix is up to about 1.0 kiloponds;
(e) the matrix comprises from about 25 mg to about 200 mg of topiramate;
(f) the matrix comprises from 10 to 40 three-dimensionally printed incremental layers;
(g) the at least one binder is present in an amount of up to about 20 wt %, based on the total weight of the dosage form;
(h) the dosage form further comprises at least one sweetener in an amount of up to about 2 wt %, based on the total weight of the dosage form;
(i) the dosage form further comprises at least one disintegrant in an amount up to 30 wt %, based on the total weight of the dosage form;
(j) the dosage form further comprises at least one glidant in an amount up to 2 wt %, based on the total weight of the dosage form; and/or
(k) the wax-coated particles of topiramate further comprise at least one surfactant.
4. The dosage form of claim 3 , wherein the thickness of the three-dimensionally printed incremental layer ranges from 0.008 inches to 0.012 inches.
5. The dosage form of claim 1 , wherein:
(a) the wax-coated particles of topiramate have an average or mean particle size in the range of from about 60 microns to about 250 microns;
(b) the topiramate particles, prior to being coated with waxy material, have an average or mean particle size in the range of from about 30 microns to about 50 microns;
(c) the dosage form comprises no more than 10 wt % of moisture, based on the total weight of the dosage form;
(d) the hardness of the dosage form ranges from 0.5 kiloponds to 3 kiloponds; and/or
(e) the dosage form comprises from 20 to 50 three-dimensionally printed incremental layers in stacked arrangement.
6. The dosage form of claim 5 , wherein the average thickness of three-dimensionally printed incremental layer ranges from about 100 microns to about 400 microns.
7. The dosage form of claim 2 , wherein the dosage form comprises the following composition: 15-20 wt % of topiramate; 20-30 wt % of waxy material; 2.5-3.5 wt of surfactant; 0.5-1.5 wt % of colloidal silicon dioxide as glidant; 4.5-10 wt % of polyvinylpyrrolidone as binder; 25-50 wt % of mannitol as binder; 4.5-10 wt % of crospovidone as disintegrant; and 1-2 wt % of sweetener.
8. The dosage form of claim 1 , wherein the dosage form is shaped as a wafer, cylinder, ring, donut, tube, cube, spheroid, ellipsoid or rectangular box.
9. A method of treating a disease, condition or disorder that is therapeutically responsive to topiramate comprising administering a dosage form of claim 1 one to three times daily to a subject in need thereof throughout a treatment period.
10. A taste-masked rapidly dispersible dosage form comprising a solid porous non-compressed three-dimensionally printed bound matrix comprising:
spray-congealed taste-masked wax-coated particles of topiramate comprising at least one waxy material and having topiramate-to-waxy material weight ratio ranging from 20:80 to 50:50; and wherein the wax-coated particles of topiramate are prepared by spray congealing a mixture comprising molten wax and particles of topiramate, and the wax is not an ionic polymer or copolymer, an acrylate polymer or copolymer, a methacrylate polymer or copolymer, or an enteric polymer or copolymer;
at least one water soluble, aqueous fluid soluble, partially water soluble or partially aqueous fluid soluble binder selected from the group consisting of water-soluble synthetic polymer, polyvinlypyrrolidone, hydropropylmethylcellulose, copovidone, pre-gelatinized cornstarch, hydroxypropylcellulose, lactose, fructose, sucrose, dextrose, sorbitol, mannitol, xylitol, and a combination thereof; and
at least one surfactant selected from the group consisting of polysorbate, poloxamer, sodium lauryl sulfate, and a combination thereof;
and wherein the total amount of wax-coated particles of topiramate ranges from 20 to 50 wt %, based on the total weight of the dosage form; and the wax-coated particles of topiramate have an average or mean particle size in the range of from about 60 microns to about 250 microns; and the topiramate particles, prior to being coated with waxy material, have an average or mean particle size in the range of from about 30 microns to about 50 microns; and
wherein the dosage form disperses in less than 90 sec when placed in aqueous fluid and topiramate remains taste-masked.
11. The dosage form of claim 10 , wherein:
(a) the dosage form further comprises at least one sweetener in an amount of up to about 2 wt %, based on the total weight of the dosage form;
(b) the at least one binder present in an amount of up to about 20 wt %, based on the total weight of the dosage form;
(c) the dosage form further comprises at least one disintegrant in an amount of up to 30 wt %, based on the total weight of the dosage form;
(d) the dosage form further comprises at least one glidant in an amount of up to 2 wt %, based on the total weight of the dosage form; and/or
(e) the wax-coated particles of topiramate further comprise at least one surfactant.
12. The dosage form of claim 10 , wherein:
(a) the matrix comprises from 10 to 40 or from 20 to 50 three-dimensionally printed incremental layers in stacked arrangement;
(b) the hardness of the matrix ranges from 0.5 kiloponds to 3 kiloponds; and/or
(c) the dosage form comprises no more than 10 wt % of moisture, based on the total weight of the dosage form.
13. The dosage form of claim 3 , wherein the at least one surfactant in the wax coated particles of topiramate is present in an amount of from 0.3 to 15 wt %, based on the total weight of wax-coated particles of topiramate included in the dosage form.
14. The dosage form of claim 11 , wherein the at least one surfactant in the wax coated particles of topiramate is present in an amount of from 0.3 to 15 wt %, based on the total weight of wax-coated particles of topiramate included in the dosage form.
15. A taste-masked rapidly dispersible dosage form comprising a three-dimensionally printed solid porous non-compressed bound matrix that disperses in less than 90 sec when placed in aqueous fluid; wherein the matrix is prepared by a three-dimensional printing process comprising depositing aqueous printing fluid onto one or more layers of bulk powder, and said bulk powder comprising:
taste-masked wax-coated particles of topiramate comprising at least one waxy material and having topiramate-to-waxy material weight ratio ranging from 20:80 to 50:50, and wherein the waxy material is not an ionic polymer or copolymer, an acrylate polymer or copolymer, a methacrylate polymer or copolymer, or an enteric polymer or copolymer;
at least one water soluble, aqueous fluid soluble, partially water soluble or partially aqueous fluid soluble binder selected from the group consisting of water-soluble synthetic polymer, polyvinlypyrrolidone, hydropropylmethylcellulose, copovidone, pre-gelatinized cornstarch, hydroxypropylcellulose, lactose, fructose, sucrose, dextrose, sorbitol, mannitol, xylitol, and a combination thereof; and
wherein the printing fluid and/or the taste-masked wax-coated particles of topiramate further comprises at least one surfactant selected from the group consisting of polysorbate, poloxamer, sodium lauryl sulfate, and a combination thereof.
16. The matrix of claim 10 , wherein the matrix is prepared by a three-dimensional printing process comprising depositing aqueous printing fluid onto one or more layers of bulk powder, said bulk powder comprising the taste-masked wax-coated particles of topiramate, and the at least one water soluble, aqueous fluid soluble, partially water soluble or partially aqueous fluid soluble binder, wherein the aqueous printing fluid and/or the tasted-masked wax coated particles of topiramate further comprise at least one surfactant.